Could Pretreatment Pan‑Immune‑Inflammation Value Predict Survival in Esophageal Cancer?
Authors:
- 9 March 2024
- journal article
- letter
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (6) , 3868-3869
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaAnnals of Surgical Oncology, 2023
- Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinomaInternational Immunopharmacology, 2023
- Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohortThoracic Cancer, 2023
- Pan-immune-inflammation Value and Prognosis in Patients With Esophageal CancerAnnals of Surgery Open, 2021